8-KEarnings & ResultsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Financial Results (Jul 15, 2009)

Filed July 15, 2009For Securities:ABT

Summary

This 8-K filing from Abbott Laboratories (ABT), dated July 15, 2009, primarily serves to announce the company's financial results for the second quarter of 2009. The report indicates that Abbott is providing these results via a press release, which is furnished as an exhibit. Investors should note that Abbott uses both GAAP and non-GAAP financial measures. The non-GAAP measures, which exclude certain specified items like acquisition-related costs, litigation settlements, and R&D expenses, are presented to offer a clearer view of ongoing business performance. Management utilizes these non-GAAP figures internally and believes they are valuable for investors in assessing the company's operational performance. However, Abbott cautions that these non-GAAP metrics should be considered alongside, and not as a replacement for, standard GAAP financial measures.

Key Highlights

  • 1Abbott Laboratories announced its second quarter 2009 financial results via an 8-K filing.
  • 2The company provided its Q2 2009 results through a press release, furnished as Exhibit 99.1.
  • 3Abbott utilizes non-GAAP financial measures in its reporting, such as net earnings and diluted EPS excluding specified items.
  • 4These non-GAAP measures are adjusted for unusual or unpredictable factors, including acquisition costs, cost reduction initiatives, litigation, and R&D expenses.
  • 5Management believes non-GAAP measures provide useful insights into ongoing business performance.
  • 6Investors are advised to consider non-GAAP measures in conjunction with, not as a substitute for, GAAP financial results.
  • 7Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer, signed the report.

Frequently Asked Questions

The primary purpose of this 8-K filing is to announce Abbott Laboratories' financial results for the second quarter of 2009 and to furnish the accompanying press release as an exhibit.

Abbott uses non-GAAP financial measures, such as net earnings and diluted EPS excluding specified items, to provide investors with a clearer understanding of ongoing business performance. These measures adjust for factors considered unusual or unpredictable, like acquisition-related costs, litigation settlements, and certain R&D expenses. Management uses these metrics internally to monitor performance.

Abbott cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with Generally Accepted Accounting Principles (GAAP). This means investors should look at both standard GAAP figures and Abbott's adjusted non-GAAP figures for a complete picture.

The detailed Q2 2009 financial results are provided in the press release dated July 15, 2009, which is furnished as Exhibit 99.1 to this 8-K filing.